TVGN - NASDAQ

Tevogen Bio Holdings Inc.

TVGN·NASDAQ

$0.25

-5.8%

HealthcareBiotechnology

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.14M

EPS-0.0936

P/E Ratio-14.94

Earnings Date03/25/2026

tvgn

Net Cash Provided by Financing Activities

Last Annual Value

12.23M

3-Year CAGR

-1%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Tevogen Bio Holdings Inc. Competitors Analysis of Net Cash Provided by Financing Activities

TVGN · NASDAQ

Company	Net Cash Provided by Financing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Tevogen Bio Holdings Inc. NASDAQ:TVGN	12.23M	46.7%	-0.4%	N/A
Whitehawk Therapeutics Inc NASDAQ:WHWK	94.38M	561.5%	-7.8%	N/A
Cognition Therapeutics, Inc. NASDAQ:CGTX	36.57M	100.7%	-7.2%	N/A
TuHURA Biosciences, Inc. NASDAQ:HURA	19.93M	95.7%	23.1%	8.9%
Instil Bio, Inc. NASDAQ:TIL	7.29M	-3.4%	-55.0%	N/A
Surrozen, Inc. NASDAQ:SRZN	85.05M	575.4%	-7.4%	N/A
Greenwich LifeSciences, Inc. NASDAQ:GLSI	12.00M	N/A	33.4%	N/A
Atossa Therapeutics, Inc. NASDAQ:ATOS	0.00	N/A	N/A	N/A
Alto Neuroscience, Inc. NYSE:ANRO	60.08M	-4.1%	13.6%	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	126.40M	40.6%	-5.9%	N/A
Nuvectis Pharma, Inc. NASDAQ:NVCT	29.11M	24.5%	13.8%	N/A

Tevogen Bio Holdings Inc. Fair Value Envelope

TVGN · NASDAQ

Our analysis suggests that TVGN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $0.2488, this represents a potential HIDDEN relative to our calculated worth for Tevogen Bio Holdings Inc..

HIDDEN

Intrinsic Value

Current Price: $0.2488

Related Guides

Blog Categories

Continue your TVGN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.